Targeted Oncology View Homepage


Ontology type: schema:Periodical     


Journal Info

START YEAR

2006

PUBLISHER

Springer International Publishing

LANGUAGE

en

HOMEPAGE

http://link.springer.com/journal/11523

Recent publications latest 20 shown

  • 2019-04-11 Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
  • 2019-04-03 Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis
  • 2019-03-30 Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
  • 2019-03-29 Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
  • 2019-03-29 Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy
  • 2019-03-23 Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
  • 2019-03-20 Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
  • 2019-03-19 Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
  • 2019-03-18 Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
  • 2019-03-04 Rucaparib: A Review in Ovarian Cancer
  • 2019-02-27 EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR
  • 2019-02-26 Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models
  • 2019-02-25 The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies
  • 2019-02 Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520
  • 2019-02 Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy
  • 2019-02 The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
  • 2019-02 Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
  • 2019-02 Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
  • 2019-02 BI 853520, a FAK-Simile of Prior FAK Inhibitors?
  • 2019-02 Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33160", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Oncology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B0000X", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Biomedicine, general", 
            "type": "DefinedTerm"
          }
        ], 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "0.798", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "1.304", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2017", 
            "ratingValue": "3.907", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2016", 
            "ratingValue": "3.438", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2015", 
            "ratingValue": "3.197", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2014", 
            "ratingValue": "4.000", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2013", 
            "ratingValue": "3.458", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "0.455", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2012", 
            "ratingValue": "2.764", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "0.455", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2011", 
            "ratingValue": "3.614", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2010", 
            "ratingValue": "2.054", 
            "type": "Rating"
          }
        ], 
        "description": "

    Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research.

    Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.

    Targeted Oncology focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

    Targeted Oncology offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal\u2019s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager\u00ae, supported by a database of international experts. This database is shared with other Adis journals.

    All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

    ", "editor": [ { "familyName": "Chopra", "givenName": "Martin", "type": "Person" } ], "id": "sg:journal.1036678", "inLanguage": [ "en" ], "isAccessibleForFree": false, "issn": [ "1776-2596", "1776-260X" ], "license": "Hybrid (Open Choice)", "name": "Targeted Oncology", "productId": [ { "name": "scopus_id", "type": "PropertyValue", "value": [ "4700152489" ] }, { "name": "wos_id", "type": "PropertyValue", "value": [ "1776-2596/TARGETED ONCOLOGY" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "101270595" ] }, { "name": "nsd_ids_id", "type": "PropertyValue", "value": [ "481133" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "11523" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "2006243434" ] }, { "name": "dimensions_id", "type": "PropertyValue", "value": [ "36678" ] } ], "publisher": { "name": "Springer International Publishing", "type": "Organization" }, "publisherImprint": "Adis", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1036678" ], "sdDataset": "journals", "sdDatePublished": "2019-03-18T11:05", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///home/ubuntu/piotr/scigraph_export/journals_20190313_sn_only.jsonl", "startYear": "2006", "type": "Periodical", "url": "http://link.springer.com/journal/11523" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1036678'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1036678'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1036678'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1036678'


     

    This table displays all metadata directly associated to this object as RDF triples.

    146 TRIPLES      21 PREDICATES      41 URIs      35 LITERALS      22 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1036678 schema:about sg:ontologies/product-market-codes/B0000X
    2 sg:ontologies/product-market-codes/H33160
    3 schema:contentRating N4fe6c041e33245daa453c6ed967002ea
    4 N50499049d43e47c2bc6a2040aee9e0a1
    5 N51d9836df81b442399a1f992f8156241
    6 N82c24883805f4ca6859c258418995c75
    7 N97ac4db0156848d6ade255c171e94111
    8 N9d5a4b8023184978a0bfc325af81b31b
    9 Nb985c5b357bf4ae6882d6e4e7a235dd4
    10 Nc6d1d7f49f0e4c448a8345df202399c4
    11 Nd1266410c5d7475b8978c85f320d72c1
    12 Nd707e5646655418e92dad33712bd7262
    13 Nd79a14c9c6fa4d90a51c44a3914af814
    14 Nfd5deecd717946d58bdb5a07e80de1be
    15 schema:description <p><i>Targeted Oncology</i> is a pragmatic tool for all physicians and scientists committed to oncology and cancer research. </p><p>Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.</p><p><i>Targeted Oncology</i> focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.</p><p><i>Targeted Oncology</i> offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.</p><p>All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.</p>
    16 schema:editor N263ddfa04b214a039f0df8b5bdfffa9f
    17 schema:inLanguage en
    18 schema:isAccessibleForFree false
    19 schema:issn 1776-2596
    20 1776-260X
    21 schema:license Hybrid (Open Choice)
    22 schema:name Targeted Oncology
    23 schema:productId N1950cd48acc743d1aeada036a169d30d
    24 N1efef68369e144f5ab4da1d76056273e
    25 N3c981b10efea43dd910477a84180999e
    26 N7aa84a4b1a45466593a8c93dc56b19bb
    27 N97584fddd5724118acad9918e28fda36
    28 Nf390f43ae679465a99b0e9d1bb4e0918
    29 Nf67d09d368e6427089215773255ef6df
    30 schema:publisher N39c43fdf1536485aa7e6dc9f15dc2a10
    31 schema:publisherImprint Adis
    32 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1036678
    33 schema:sdDatePublished 2019-03-18T11:05
    34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    35 schema:sdPublisher Ne87ab7a098f446e9af0e65938f8af6b6
    36 schema:startYear 2006
    37 schema:url http://link.springer.com/journal/11523
    38 sgo:license sg:explorer/license/
    39 sgo:sdDataset journals
    40 rdf:type schema:Periodical
    41 N138f03e6c84444a9aee59e726ab56e8d rdf:first snip
    42 rdf:rest rdf:nil
    43 N1950cd48acc743d1aeada036a169d30d schema:name springer_id
    44 schema:value 11523
    45 rdf:type schema:PropertyValue
    46 N1efef68369e144f5ab4da1d76056273e schema:name dimensions_id
    47 schema:value 36678
    48 rdf:type schema:PropertyValue
    49 N263ddfa04b214a039f0df8b5bdfffa9f rdf:first N2f15ae9802384b30b187f263f50d821e
    50 rdf:rest rdf:nil
    51 N2f15ae9802384b30b187f263f50d821e schema:familyName Chopra
    52 schema:givenName Martin
    53 rdf:type schema:Person
    54 N39c43fdf1536485aa7e6dc9f15dc2a10 schema:name Springer International Publishing
    55 rdf:type schema:Organization
    56 N3c981b10efea43dd910477a84180999e schema:name nlm_unique_id
    57 schema:value 101270595
    58 rdf:type schema:PropertyValue
    59 N42902452dc7b4f5da9ffd6fb436ebcba rdf:first impact_factor_wos
    60 rdf:rest rdf:nil
    61 N4a413b62cdb34af29bcc4a7ca29de40f rdf:first impact_factor_wos
    62 rdf:rest rdf:nil
    63 N4b629e92b23b4dc7b06e03464fb2d279 rdf:first impact_factor_wos
    64 rdf:rest rdf:nil
    65 N4fe6c041e33245daa453c6ed967002ea schema:author N6d8b0cdca39f4d4d97308aa57b177a7a
    66 schema:dateCreated 2015
    67 schema:ratingValue 3.197
    68 rdf:type schema:Rating
    69 N50499049d43e47c2bc6a2040aee9e0a1 schema:author N55c9e53263664568baa64532fde5ed43
    70 schema:dateCreated 2017
    71 schema:ratingValue 3.907
    72 rdf:type schema:Rating
    73 N51d9836df81b442399a1f992f8156241 schema:author N76d685b3c65e481da0b6234ffe0d4895
    74 schema:dateCreated 2009
    75 schema:ratingValue 0.455
    76 rdf:type schema:Rating
    77 N55c9e53263664568baa64532fde5ed43 rdf:first impact_factor_wos
    78 rdf:rest rdf:nil
    79 N57f086d45d0c4b13bc84b1f754d2cc97 rdf:first impact_factor_wos
    80 rdf:rest rdf:nil
    81 N6d8b0cdca39f4d4d97308aa57b177a7a rdf:first impact_factor_wos
    82 rdf:rest rdf:nil
    83 N76d685b3c65e481da0b6234ffe0d4895 rdf:first impact_factor_wos
    84 rdf:rest rdf:nil
    85 N7aa84a4b1a45466593a8c93dc56b19bb schema:name nsd_ids_id
    86 schema:value 481133
    87 rdf:type schema:PropertyValue
    88 N7fc2181063ab4aa9a44aeb92825d9b87 rdf:first sjr
    89 rdf:rest rdf:nil
    90 N82c24883805f4ca6859c258418995c75 schema:author N57f086d45d0c4b13bc84b1f754d2cc97
    91 schema:dateCreated 2016
    92 schema:ratingValue 3.438
    93 rdf:type schema:Rating
    94 N97584fddd5724118acad9918e28fda36 schema:name lccn_id
    95 schema:value 2006243434
    96 rdf:type schema:PropertyValue
    97 N97ac4db0156848d6ade255c171e94111 schema:author N138f03e6c84444a9aee59e726ab56e8d
    98 schema:ratingValue 0.798
    99 rdf:type schema:Rating
    100 N9d5a4b8023184978a0bfc325af81b31b schema:author N4a413b62cdb34af29bcc4a7ca29de40f
    101 schema:dateCreated 2014
    102 schema:ratingValue 4.000
    103 rdf:type schema:Rating
    104 Na6ebbb142cc64845a4830e92245ee3b2 rdf:first impact_factor_wos
    105 rdf:rest rdf:nil
    106 Na76d7ec65238488090a76e66fb9fff5e rdf:first impact_factor_wos
    107 rdf:rest rdf:nil
    108 Nb985c5b357bf4ae6882d6e4e7a235dd4 schema:author Na6ebbb142cc64845a4830e92245ee3b2
    109 schema:dateCreated 2009
    110 schema:ratingValue 0.455
    111 rdf:type schema:Rating
    112 Nc6d1d7f49f0e4c448a8345df202399c4 schema:author N42902452dc7b4f5da9ffd6fb436ebcba
    113 schema:dateCreated 2011
    114 schema:ratingValue 3.614
    115 rdf:type schema:Rating
    116 Nd1266410c5d7475b8978c85f320d72c1 schema:author N7fc2181063ab4aa9a44aeb92825d9b87
    117 schema:ratingValue 1.304
    118 rdf:type schema:Rating
    119 Nd707e5646655418e92dad33712bd7262 schema:author Na76d7ec65238488090a76e66fb9fff5e
    120 schema:dateCreated 2010
    121 schema:ratingValue 2.054
    122 rdf:type schema:Rating
    123 Nd79a14c9c6fa4d90a51c44a3914af814 schema:author N4b629e92b23b4dc7b06e03464fb2d279
    124 schema:dateCreated 2012
    125 schema:ratingValue 2.764
    126 rdf:type schema:Rating
    127 Ne87ab7a098f446e9af0e65938f8af6b6 schema:name Springer Nature - SN SciGraph project
    128 rdf:type schema:Organization
    129 Neab0b7258f144c558193700224eed6dc rdf:first impact_factor_wos
    130 rdf:rest rdf:nil
    131 Nf390f43ae679465a99b0e9d1bb4e0918 schema:name scopus_id
    132 schema:value 4700152489
    133 rdf:type schema:PropertyValue
    134 Nf67d09d368e6427089215773255ef6df schema:name wos_id
    135 schema:value 1776-2596/TARGETED ONCOLOGY
    136 rdf:type schema:PropertyValue
    137 Nfd5deecd717946d58bdb5a07e80de1be schema:author Neab0b7258f144c558193700224eed6dc
    138 schema:dateCreated 2013
    139 schema:ratingValue 3.458
    140 rdf:type schema:Rating
    141 sg:ontologies/product-market-codes/B0000X schema:inDefinedTermSet sg:ontologies/product-market-codes/
    142 schema:name Biomedicine, general
    143 rdf:type schema:DefinedTerm
    144 sg:ontologies/product-market-codes/H33160 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    145 schema:name Oncology
    146 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...